The U.S. Food and Drug Administration (FDA) announced on 2025-10-14 that the label for Glipizide and Metformin Hydrochloride now includes a boxed warning regarding the risk of metformin-associated lactic acidosis. This serious condition has been linked to postmarketing cases resulting in death, hypothermia, hypotension, and resistant bradyarrhythmias.
Background
Metformin, a component of Glipizide and Metformin Hydrochloride, is known to carry a risk of lactic acidosis. Lactic acidosis is a rare but severe metabolic complication that can occur due to metformin accumulation, particularly in patients with predisposing conditions. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by non-specific symptoms. The boxed warning highlights the critical importance of recognizing its symptoms and risk factors to prevent severe outcomes.
What this means
The addition of a boxed warning to the Glipizide and Metformin Hydrochloride label underscores the FDA's emphasis on patient safety regarding metformin-associated lactic acidosis. Clinicians prescribing this medication must be acutely aware of the risk factors, which typically include renal impairment, concomitant use of certain drugs, and conditions that lead to tissue hypoperfusion or hypoxia. Patients should be educated on the subtle signs of lactic acidosis, such as malaise, myalgia, respiratory distress, and abdominal pain, and advised to seek immediate medical attention if these symptoms arise. This warning serves as a crucial reminder for healthcare providers to carefully assess patient risk profiles and monitor for potential complications during treatment with metformin-containing products.
Source
This information regarding the label revision was provided by the U.S. Food and Drug Administration (FDA) on 2025-10-14, detailing the presence of a boxed warning on the Glipizide and Metformin Hydrochloride label. The official document is accessible via dailymed.nlm.nih.gov.